



# Monitoring of patients with GSD

---

DR. HOSSEIN MORAVEJ


PEDIATRIC ENDOCRINOLOGY AND METABOLISM

SHIRAZ UNIVERSITY OF MEDICAL SCIENCES


# GSD type 1

## Glycogen Storage Disease, Type 1 (GSD-1)

*Occurring mainly in the liver...*



## Clinical manifestations





# GSD



Most commonly present between **three to six months** of age with:

- Hepatomegaly
- Hypoglycemia
- Poor growth, and
- Doll-like facies



# Hypoglycemia


---

- Poor fasting tolerance, especially infants and young children,
- May develop hypoglycemia within **an hour or two after a meal**.
- Hypoglycemia is the **hallmark** finding in patients with GSD I.
- Unlike other GSDs, hypoglycemia in GSD I is characterized by **hypoketosis** due to inhibition of fatty acid oxidation by malonic acid .

- 
- **Symptoms** of hypoglycemia include:
  - fatigue,
  - irritability,
  - nighttime waking to feed
  - Decreased level of consciousness
  - seizures.
  - Patients often **adapt to hypoglycemia** and may be asymptomatic despite low blood glucose values (<40 mg/dL).

# Lactic acidosis

- Inability to break down glycogen into glucose results in shunting of G6P down the **glycolytic pathway** with resultant lactic acid production.



# Hyperuricemia

---

- Secondary to **decreased renal clearance** and **increased production** via degradation of adenine nucleotides.
- Gout rarely develops before puberty.



# Hyperlipidemia

---

- Especially **hypertriglyceridemia**
- **Xanthoma** formation and **pancreatitis**.
- De novo triglyceride synthesis has been shown to increase over 10-fold in affected individuals, and the conversion of very-low-density lipoprotein (VLDL) to low-density lipoprotein (LDL) is delayed.

# Hematologic

---

- Anemia, uncommon in treated patients:
- Result from chronic **kidney** disease, **nutritional** deficiencies, hemorrhage of hepatic **adenomas**, **enterocolitis** in type Ib patients, and other factors.
- **Platelet dysfunction**, which is **related to dyslipidemia**, can result in easy bruising and epistaxis.

# Hematologic

---

- Patients with **GSD Ib** also have intermittent or chronic **neutropenia and neutrophil dysfunction**.
- neutropenia was documented **before one year** of age in 64 percent of patients but was first noted between six and **nine years** in 18 percent.
- Neutropenia was **intermittent without a clear cyclical course in most patients** and persistent in others

# Gastrointestinal

---

- **Perioral and perianal** infections and abscesses, and
- Inflammatory bowel disease (**IBD**) are common in GSD Ib.
- IBD can occur in GSD Ia and may be underrecognized

# Endocrine

---

- **Short stature** is common if patients are **not appropriately managed**.
- **Puberty is often delayed**, and menstrual cycles are frequently **irregular**.
- **Polycystic ovaries** and menorrhagia have been observed.
- **Fertility** does not seem to be reduced, and successful pregnancies without the use of assistive reproductive measures have been reported.
- An increased prevalence of **thyroid autoimmunity and hypothyroidism** has been reported in patients with **GSD Ib**.
- **Vitamin D** levels are often low.

# Renal

---

- **Glycogen accumulation** in the kidney
- **Proteinuria, hematuria, nephrocalcinosis**, and altered creatinine clearance typically follow a period of asymptomatic hyperfiltration.
- **Stones** result both from **hypercalciuria and hyperuricosuria**.
- The kidney appears **enlarged**.

# Hypertension

---

- Common
- Onset is typically in the **second decade** or later.
- A subset of patients develop progressive renal insufficiency and end-stage kidney disease

# Neurologic

---

- Hypoglycemic seizures
- **IQ is normal.**
- **Brain function and structure** may be altered as a result of recurrent, severe hypoglycemia.
- **MRI** abnormalities included dilation of the occipital horns and/or hyperintensity of subcortical white matter in the occipital or parietal lobes



# Hepatic adenomas

---

- Most adults develop liver adenomas in the **second to third decade** of life.
- The adenomas may lead to intrahepatic **hemorrhage** and undergo **malignant transformation** in approximately 10 percent of cases

## Bone density

---

**Osteoporosis** is seen in over half of adult patients with GSD I.

Due to a chronic **lactic acidosis**, the effect of **cortisol release** (in response to hypoglycemia) on osteoblasts, and treatment of GSD itself, which involves **dietary** restriction of lactose and galactose that leads to vitamin D deficiency

# Pulmonary hypertension

---

A small number of patients develop pulmonary hypertension, which can lead to progressive heart failure.

---

# DIAGNOSIS



# DIAGNOSIS

---

GSD I should be **suspected in** patients with:

- Hypoglycemia
- lactic acidemia
- Hypertriglyceridemia
- Hyperuricemia
- Hepatomegaly

---

**DNA testing** is necessary to confirm the diagnosis of GSD Ia or Ib.

Liver biopsies for histologic studies and enzyme analysis were performed historically but are rarely necessary nowadays.

# DIFFERENTIAL DIAGNOSIS

---

- Other hepatic forms of GSD that cause hypoglycemia:
- **Types 0, III, VI, and IX.**
- GSD type III may have extremely elevated **AST and ALT** and milder hypoglycemia. In addition, uric acid and lactic acid are normal.
- **Ketosis** is much more pronounced in GSD types 0, III, VI, and IX compared with type I.
- GSD type 0 does not cause **hepatomegaly**.

- 
- **Genetic testing** is necessary to confirm the specific type of GSD.





shutterstock.com · 2081050255

# Goal

---

- The goal of treatment is maintenance of **physiologic glucose** levels.
- Other clinical and biochemical parameters, such as somatic **growth**, lactic **acidosis**, and **hypertriglyceridemia**, improve in parallel with improved glucose control.

# Monitoring

---

**Preprandial** blood glucose >63 to 72 mg/dL

- **Urine lactate**/creatinine ratio <0.06 mmol/mmol
- Serum **uric acid** concentration in high normal range for age
- Venous blood **bicarbonate** >20 mEq/L
- Serum **triglyceride** concentration < 530 mg/dL
- Normal **fecal alpha-1 antitrypsin** concentration for GSD Ib
- **Body mass index** between 0.0 and + 2.0 standard deviations

# Prevention of hypoglycemia

---

- **Infants** should be **fed at regular**, age-appropriate intervals. In rare instances, they may require more frequent feeding.
- Early infants should **not be allowed to sleep through the night**. Some may require **continuous feeds** through a nasogastric or gastrostomy tube. An optimal infusion should provide 8 to 10 mg/kg/minute of glucose for an infant and 4 to 8 mg/kg/minute of glucose in an older child.
-

# Prevention of hypoglycemia

---

**After one year** of age, children should be given at least three daily meals with **snacks** in between.

**Between meals:** frequent oral administration of glucose, usually in the form of **uncooked cornstarch**

In many cases, a dose of cornstarch is needed **during the night**.

.

# cornstarch

---

Long-term treatment with uncooked cornstarch **improves growth** in GSD I

Adverse effects of uncooked cornstarch include **diarrhea**, increased **flatulence**, and excess **weight gain**.

## cornstarch

---

The dose of uncooked cornstarch is **1.6 g/kg every three to four** hours for young children and

**1.7 to 2.5 g/kg every four to six hours** for older children, adolescents, and adults. (1 tablespoon equals approximately 8.6 gram)

Dosing is adjusted for the individual patient.

# cornstarch

---

Since infants do not digest cornstarch well due to lack of **salivary amylase** expression, it is recommended to begin cornstarch therapy **after 6 to 12 months** of age, when amylase activity increases.



# Treatment of lactic acidosis

---

- Oral citrate or bicarbonate
- **Potassium citrate is preferred** over bicarbonate because hypocitraturia appears to worsen with age in GSD Ia.
- They also alkalinizes the urine and **decreases the risk of urolithiasis and nephrocalcinosis**

# Treatment of hyperuricemia

---

- No consensus
- **Allopurinol** can be used in patients with persistently elevated uric acid or with recurrent attacks of gout.
- **Colchicine** may be used during acute attacks.
- Use of **medium-chain triglyceride** oil was shown in a small study to improve uric acid levels and reduce carbohydrate requirements.

# Treatment of hyperlipidemia

---

- Lipid-lowering agents such as **HMG-CoA reductase inhibitors** and **fibrate** may be used.
- **MCT** may be effective at reducing triglyceride and lactic acid levels by improving fatty acid oxidation and reducing glycolysis but require additional evaluation.
- However, hyperlipidemia in patients with GSD I **only responds partially to drug** therapy and/or dietary measures. It resolves completely after liver transplantation.

---

Fish oil does not persistently lower serum triglyceride and cholesterol concentration and may increase atherogenesis by increasing lipoprotein oxidation.

# Neutropenia

---

- Patients with GSD Ib and neutropenia should be treated with **G-CSF**.
- G-CSF increases neutrophil count, decreases the frequency and severity of infections, and improves inflammatory bowel symptoms.
- Splenomegaly is the most serious complication of G-CSF.

- 
- Reactive oxygen species are thought to play a role in activating apoptosis in neutrophils of patients with GSD Ib, **antioxidant therapy** may be beneficial.

Supplementation with **vitamin E** has been shown to increase mean **neutrophil count**, decrease the frequency and severity of **infections**, and, in some cases, allow for **dose reduction of G-CSF**.

# Anemia

---

- May need **iron supplementation** and **erythropoietin**, depending upon the severity.

## Short stature

---

**Growth hormone** does not affect the final height and **should not be used**, because it can lead to the development of or an increase in the size or number **of liver adenomas**.

**Good metabolic control** leads to improved height and weight.



# Osteoporosis

---

Dual-energy x-ray absorptiometry (DXA) scans and vitamin D 25-OH levels should be checked regularly to monitor bone density and need for vitamin D supplementation.

# Renal disease

---

- A **renal ultrasound** should be obtained **annually** to assess for renal enlargement and nephrolithiasis.
- **BUN, creatinine, urinalysis**, quantitation of **microalbumin**, and other renal function studies should be checked at routine intervals, typically **annually in children** and **every six months in adults**.
- Alkalinization of the urine with oral citrate decreases the risk of stone formation.

---

**ACE inhibitor** or angiotensin receptor blocker (**ARB**) should be started in patients with **persistent microalbuminuria** to decrease deterioration of renal function.

Hypertension that persists despite ACE inhibition should also be treated.

**Kidney transplant** can be performed in patients with end-stage kidney disease.

# Hepatocellular carcinoma

---

- Hepatocellular carcinoma (**HCC**) is a known late complication GSD I.
- Adenoma to HCC transformation may occur **despite good metabolic control**.
- A liver **ultrasound** should be performed **every 12 to 24 months in children <18 years of age** to screen for HCC.
- CT or MRI with contrast is recommended every 6 to 12 months in older patients.
- **Oral contraceptive pills are contraindicated** in women with GSD I since estrogen increases the risk for hepatic adenomas. However, **progestin-only** contraceptives are an option.

# Pulmonary hypertension

---

- An **echocardiogram** should be performed starting at **10 years** of age to screen for pulmonary hypertension.
- **Every three years** or sooner if clinically indicated.

# Liver transplantation

---

## **Indications:**

poor metabolic control,  
worsening adenomas,  
HCC, and/or  
liver failure

# Liver transplantation

---

The 1-, 5-, and 10-year survival rates are 82, 76, and 64 percent, respectively.

Transplantation results in **resolution of hypoglycemia** and secondary metabolic disturbances including lactic **acidosis, hypertriglyceridemia, and hyperuricemia.**

Patients can eat a **normal diet** after liver transplantation. **Growth deficiency and neutropenia often persist** in GSD Ib after transplantation.

